SARS-CoV-2 Vaccine Acceptance: We May Need to Choose Our Battles
A vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely considered a key strategy to ending transmission of the virus and getting our social and economic lives “back to normal.” All eyes are on Operation Warp Speed and other rapid vaccine development initiatives, with optimistic projections for a safe and effective vaccine being approved in the next few months. But as Fisher and colleagues (1) note in their analysis of attitudes toward a potential SARS-CoV-2 vaccine, published in this issue, approval of a vaccine is just the starting line of a long and challenging race to achieve widespread acceptance of 1 or more novel coronavirus vaccines.